A Novel Derivative of Doxorubicin, AD198, Inhibits Canine Transitional Cell Carcinoma and Osteosarcoma Cells In Vitro

September 2015 in “ Drug Design Development and Therapy ”

Maria Cekanova, Kusum Rathore

Studysummary This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on dovepress.com →

PubMed
DOI

Discuss this study in the Community →

Similar research 5

Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma Journal of Veterinary Internal Medicine · 2014
Synthesis, Anticancer, and Molecular Docking Studies of 2-(4-Chlorophenyl)-5-Aryl-1,3,4-Oxadiazole Analogues Medicinal chemistry · 2013
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer Clinical breast cancer · 2003
Design, Synthesis and Anti-Tumor Evaluation of Novel Thiohydantoin Congeners as Androgen Receptor Antagonists With In Vivo Study Journal of molecular structure · 2024
Thiohydrazides in the Synthesis of Functionalized Extranuclear Heterosteroids 2023

Related Community Posts Join

6 / 1000+ results

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 2 years ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

community OND-1 "Cyclosporine A” New hair loss treatment

in Research/Science 28 upvotes 5 months ago

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

community Best available SARD right now?

in Treatment 3 upvotes 5 months ago

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

community Is there any new drug that looks promising ?

26 upvotes 2 years ago

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

community AH-001 another topical AR degrader beside GT20029, completed Phase I

8 upvotes 10 months ago

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi

15 upvotes 7 years ago

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.